Neurobiological differences on populational level.
At present, 13% of world population are suffering from neuropsychiatric disorders. Prevention and treatment of these pathological conditions are very important. New research strategies are needed for the creation of effective methods for controlling of neuropsychiatric disorders. International collaborative research projects within WHO's activities in psychopharmacology and biological psychiatry with the participation of 12 countries representing different world regions have been organized and successfully finalized. The author discusses some of these in the Festschrift for Dr. Corneille Radouco-Thomas.
Vartanian
Felix
F
Ministry of Health, Russian Academy of Advanced Medical Studies, 123995, Moscow, Barrikadnaya str. 2, Russia. rmapo_ivc@mtu-net.ru
D000639:Amitriptyline / Q000097:blood; D000928:Antidepressive Agents / Q000627:therapeutic use; D006801:Humans; D001523:Mental Disorders / Q000453:epidemiology* / Q000235:genetics / Q000378:metabolism / Q000628:therapy; D009446:Neurobiology / Q000706:statistics & numerical data*; D044382:Population Groups / Q000706:statistics & numerical data; D018800:Thy-1 Antigens / Q000378:metabolism
D000928:Antidepressive Agents; D018800:Thy-1 Antigens; D000639:Amitriptyline